Normal IgG protects against acute graft-versus-host disease by targeting CD4+CD134+ donor alloreactive T cells

European Journal of Immunology

Volumn 31, Issue 9, 2001, Pages 2781-2790

  Caccavelli, Laure ^a   Field, Anne Christine ^a   Betin, Virginie ^a   Dreillard, Laetitia ^a   Belair, Marie France ^a   Bloch, Marie Françoise ^a   Bruneval, Patrick ^a   Kazatchkine, Michel ^a   Bellon, Blanche ^a  

^a INSERM   (France)

Author keywords

Acute graft versus host disease; Apoptosis; CD134+ T cell; Normal IgG; Rat

Indexed keywords

ALLOANTIGEN; CD4 ANTIGEN; CELL MARKER; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 10;

ACUTE DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL TRANSFER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DONOR; DRUG EFFECT; GRAFT VERSUS HOST REACTION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; NONHUMAN; PARENT; PRIORITY JOURNAL; RAT; RAT STRAIN; RECIPIENT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD27; APOPTOSIS; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; GRAFT VS HOST DISEASE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIGENS; RATS; RATS, INBRED LEW; RECEPTORS, OX40; RECEPTORS, TUMOR NECROSIS FACTOR; TH1 CELLS; TH2 CELLS;

EID: 0034805686     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4141(200109)31:9<2781::AID-IMMU2781>3.0.CO;2-Z     Document Type: Article

References (26)

1. Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunological diseases
2. Role of cytotoxic T lymphocytes in the prevention of lupus-like disease occurring in a murine model of graft-vs-host disease
3. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease
4. + donor T cells fail to induce experimental acute graft-versus-host disease
5. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12
6. Kinetics of T cell activation in acute and chronic forms of murine graft-versus-host disease
7. + T cell activation and IFN-gamma production
8. Expression of the T cell activation antigen, OX-40, identifies alloreactive T cells in acute graft-versus-host disease
9. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation
10. + T cells
11. Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis
12. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg)
13. A major role for the Fas pathway in acute graft-versus-host disease
14. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway
15. Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion
16. Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40)
17. In vitro investigation of immunoglobulin treatment mechanisms in autoimmune diseases
18. Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG
19. Pooled human IgG modulates cytokine production in lymphocytes and monocytes
20. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein
21. Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric chloride-induced autoimmune disease of Brown-Norway rats
22. Immunoglobin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse
23. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation
24. Expression of CD134 (OX-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease
25. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use
26. Transient expression of the 5α-reductase type 2 isozyme in the rat brain in late fetal and early postnatal life